Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
